Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infus...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., Kimby, Eva
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2009
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670786/
https://ncbi.nlm.nih.gov/pubmed/19015393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-09-177329
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky